Objective To observe the effect of nimodipine on the treatment of hypertensive cerebral hemorrhage(HCT) .Method Patients with HCT in 24 hours were randomLy divided into control group and treatment group.The treatment group was given 50mL(10mg) nimodipine injection for 14 days and then was orally given 40 mg nimodipine for another 14 days.The control group was given all treatment drug except nimodipine.The absorption of hemorrhage and edema,CSS and BI were observed and compared between the two groups.Result The hemorrhage and edema were better absorbed in the treatment group(t=2.14,P

Studies have shown that most of the sequence in the mammalian genome is transcribed into long noncoding RNAs (lncRNAs). Their crucial roles in gene regulation are becoming a hotspot in current biomedical research. LncRNAs can control gene activities through multiple mechanisms such as: 1) direct or indirect regulation of gene expression via cis-/trans-action or function as protein baits in the nucleus; 2) affecting the stability and the translational process of mRNA; 3) functioning as competitors to regulation of microRNA; 4) binding to transcription factors. Recent studies have highlighted the significance of lncRNAs in development and diseases, and their potentials in future clinical application.

In recent years, with the development of some new techniques based on bronchoscopic skills, such as endobronchial ultrasonography, autofluorescence bronchoscopy, electromagnetic navigation bronchoscopy, fibered confocal fluorescence microendoscopy and optic coherence tomography of the advent of technology, which solved the shortcomings of traditional technology from different areas and dimensions. Although these techniques need to be improved and clinical verified further, it was believed that the great impact on diagnosis and treatment of lung cancer should be made by them.

Objective To investigate effect of pidotimod on TH1/TH2 balance and immune factor in patients with severe trauma.Methods 90 cases with severe chest trauma patients were randomly divided into two groups.45 cases in control group were treated by conventional anti-inflammatory treatment, 45 cases in experimental group on base of control group with pidotimod 800mg /times, 1 times daily.After treatment, the serum levels of IL-4, IFN-γ, IL-2, IL-10, IL-17,IgM, IgA and IgG were compared.Results Compared with before treatment, indexes were improved(P<0.05). Compared with the control group, IL-4 level was lower, IFN-γlevel was higher, IFN-γ/IL-4 was higher(P<0.05).IL-2, IL-10, IL-17 level was higher(P<0.05).IgA, IgM, IgG level was higher(P<0.05).Conclusion Pidotimod can balance the TH1/TH2 in the patients with severe trauma, and adjust the serum levels of IgM, IgA and IgG,can be used in clinical application.

Objective To investigate the role of antisense RNA of plasminogen activator inhibitor 1 (PAI 1) in regulating the expression of PAI 1 and vascular endothelial growth factor (VEGF) in aorta endothelial cells (EC) cultured in vitro. Methods The second extron of PAI 1 was amplified by polymerase chain reaction(PCR) and the product was inserted into eukaryotic cell expression vector pcDNA3.1(-) to construct PAI 1 antisence RNA recombinant plasmid. The recombinant plasmid was transfected into EC and the PAI 1 expression was detected by immunohistochemistry, Westernblot and ELISA. The effects of PAI 1 variation on VEGF were examined by immunofluorescence method. Results PAI 1 antigen was the lowest (0 017 ng/ml) in cells and the immunofluorescence representing the expression of VEGF in the cytoplasm showed the weakest at the third day after transfection. At the fifth day, PAI 1 antigen increased to 0 093 ng/ml with VEGF expression increased correspondingly. At the seventh day, PAI 1 antigen(0 143 ng/ml) and VEGF increased closed to normal level. Conclusions PAI 1 antisense RNA blocked the translation of PAI 1 proteins effectively and inhibited the expression of VEGF in aorta endothelial cells.

Objective: To study the effect of levosimendan treatment in patients of dilated cardiomyopathy (DCM) with different heart fraction. Methods: A total of 145 DCM patients were enrolled, based on left ventricular ejection fraction (LVEF), the patients were divided into 3 groups: Mild heart failure (HF) group, the patients with LVEF≤45%,n=15, Moderate HF group, LVEF≤40%,n=58 and Severe HF group, LVEF≤30%,n=72. LVEF, left atrial diameter (LAD), left ventricular end-diastolic diameter (LVEDD) and blood levels of BNP were examined and compared at prior and 7 days after levosimendan treatment respectively. Results: Compared with prior treatment, fater7 days of levosimendan medication, LVEF was elevated at certain degree in all 3 groups, while the statistic improvement was only found in Severe HF group (26.06±3.59) % vs (24.79±2.81) %,P<0.05; LAD and LVEDD had no obvious changes with levosimendan medication in all 3 groups,P>0.05. After levosimendan treatment, blood levels of BNP were decreased in all 3 groups as in Mild HF group (604.80±631.87) pg/ml vs (1252.17±1435.39) pg/ml, Moderate HF group (2369.78±2478.59) pg/ml vs (3206.90±2677.15) pg/ml and Severe HF group (4879.63±5302.42) pg/ml vs (6004.46±5041.59) pg/ml, allP<0.05. The differences of BNP level between prior and after levosimendan treatment, the ratio for BNP reduction were similar among 3 groups, allP>0.05. Conclusion: Levosimendan may, in short term, improve the cardiac function in DCM patients with mild, moderate and severe HF with similar degree; while it could not really change the cardiac structure.

Cardio-protective action of synthetic peptide 6A, fibrinogen degradation segment, was observed on the myocardial injury model produced by subcutaneous injection of iso-proterenol (30 mg?kg-1-d-1) into rat. Treatment with peptide 6A (50 ?mol?kg-1? d-1,iv) significantly ameliorated isoproterenol-induced myocardial lesion, inhibited release of myocardial creatine phosphokinase, ?-hydroxybutyratedehydrogenase, lactate dehydrogenase and gluta-mate-oxaloacetate transaminase, lowered plasma fibrinogen content,and markedly prevented myocardial calcium accumulation. The results suggest that peptide 6A could have potential significance for clinical therapy of ischemia heart diseases.

Adult ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Hepatitis B, Chronic ; complications ; drug therapy ; Humans ; Liver Cirrhosis ; drug therapy ; etiology ; Male ; Middle Aged ; Phytotherapy ; Tablets

10.3969/j.issn.2095-4344.2013.25.011

Bronchiectasis combined with pulmonary carcinoma in situ is very rare condition.This study reported four cases and reviewed some literatures.The data of 66 cases treated from August 2012 to October 2013,whose initial diagnoses as bronchiectases were analysed.Four cases were diagnosed postoperatively as bronchiectasis with pulmonary carcinoma in situ after sugery,accounted for 6％ of surgical patients for bronchiectasis.Bronchiectasis has the risk of combined with pulmonary carcinoma in situ,this should be brought to the attention.